Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-04-19
    E.g., 2018-04-19

Archive Search

Pages

255788 items
5:03 PM, Apr 19, 2018  |  BC Extra | Company News

Shire rejects third Takeda bid, as Allergan drops out

Shire plc (LSE:SHP; NASDAQ:SHPG) said Thursday its board has unanimously rejected three separate takeout offers from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), culminating at the most recent bid valued at £44 billion ($62.7 billion) in which...
5:00 PM, Apr 19, 2018  |  BC Innovations | Tools & Techniques

Structured outlook

A Cell study capturing hundreds of E. coli mRNA structures makes the case that complex, functionally relevant RNA structures are the rule, not the exception, and builds confidence that mRNAs -- once widely considered undruggable...
4:58 PM, Apr 19, 2018  |  BC Innovations | Product R&D

Automation navigation

Last year’s approvals of the first two CAR T therapies have prompted the field to get serious about industrializing manufacturing of the cells to improve reproducibility and lower costs. While stakeholders agree that automation will...
4:46 PM, Apr 19, 2018  |  BC Extra | Company News

FDA says Olumiant's thrombosis signal not a JAK class effect

FDA reviewers raised concerns over a possible increased risk of thrombosis with rheumatoid arthritis candidate Olumiant baricitinib from Eli Lilly and Co. (NYSE:LLY) and partner Incyte Corp. (NASDAQ:INCY). In briefing documents released Thursday ahead of...
4:25 PM, Apr 19, 2018  |  BC Extra | Company News

Non-profit KEI sues NIH to block Gilead's anti-CD30 CAR T patent

Non-profit Knowledge Ecology International filed a lawsuit against the National Institutes of Health seeking to invalidate a license granting the Kite Pharma Inc. subsidiary of Gilead Sciences Inc. (NASDAQ:GILD) rights to patents covering an anti-CD30...
3:56 PM, Apr 19, 2018  |  BC Extra | Company News

CHMP rebuffs AB Science’s masitinib in ALS

EMA’s CHMP recommended against approval of masitinib (AB1010) from AB Science S.A. (Euronext:AB) to treat amyotrophic lateral sclerosis. The company said it plans to address the issues raised by the committee and expects a second...
3:47 PM, Apr 19, 2018  |  BC Extra | Preclinical News

Synthetic tattoo could detect asymptomatic cancer

A team from ETH Zurich developed a synthetic cellular sensor that darkens a patient's skin in the presence of hypercalcemia -- a disorder associated with many cancers that often arises before signs of cancer --...
2:45 PM, Apr 19, 2018  |  BC Extra | Company News

Novartis reports first Kymriah sales, Cosentyx miss

Novartis AG (NYSE:NVS; SIX:NOVN) reported $580 million in 1Q18 sales of autoimmune drug Cosentyx secukinumab, shy of analysts' $635 million consensus estimate. The pharma also reported for the first time sales of CAR T therapy...
1:43 PM, Apr 19, 2018  |  BC Extra | Company News

Panel: Risk/benefit favorable for GW's Epidiolex

An FDA advisory committee voted 13-0 on Thursday that the benefit-risk profile of Epidiolex cannabidiol from GW Pharmaceuticals plc (NASDAQ:GWPH) was favorable to treat seizures in patients with Lennox-Gastaut syndrome and Dravet syndrome ages 2...
1:27 PM, Apr 19, 2018  |  BC Extra | Financial News

Apellis raises $140.3M in follow-on

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) raised $140.3 million late Wednesday through the sale of 5.5 million shares at $25.50 in a follow-on underwritten by Citigroup, J.P. Morgan and Cowen. The price is a 15% discount to...

Pages